An observational study in Emphysema or COPD, sponsored by Pulmonx Corporation. Completed at 12 sites in France. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Pulmonx Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Emphysema with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Emphysema · France.
Among the 27 studies in Emphysema with a site in France, this one is the only one that started in 2021, is one of 8 observational ones, and was the 19th registered.
382 studies on the registry are indexed under Emphysema; 58 are open to participants now.
Browse Emphysema studies →6 of the 27 studies in Emphysema with a site in France are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 40–75
University Hospital, Bordeaux · Sites in France
Ages 18+
Pulmair Medical, Inc. · Sites in France, Netherlands
Ages 22+
University Hospital, Limoges · Sites in France
Ages 35–80
Pulmonx Corporation · Sites in France, United States, Australia and 7 more countries
Ages 40–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 49 Emphysema studies recruiting now, 27 (55%) set no upper age limit and 8 (16%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 3
First in 2005; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 131 across 111 observational studies indexed under Emphysema.
Median enrollment 102 across the 19 interventional studies, 193 across the 8 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 27 have an industry lead sponsor. The 10 most frequent:
Pulmonx Corporation is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Pulmonx Corporation has 9 studies filed under Emphysema — fewer than ten, so there is no comparison to draw.
2 of the studies in Emphysema with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035120Pulmonx CorporationAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | 2027-06-30 |
| NCT07086339Pulmair Medical, Inc.A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Emphysema with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support the renewal of the inscription of the Zephyr Valve on the list LPPR (Art 165-1) in France.
This is a multi-center, single-arm, prospective Registry to be conducted at a minimum of 12 study centers. Approximately 150 patients with severe emphysema undergoing Zephyr Valve treatment will be enrolled and followed out to 3 years. Assessments will be performed at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure.
Patients prescribed the Zephyr Valve treatment will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. Safety and effectiveness of the Zephyr Valve treatment will be evaluated post-treatment based on data collected out to 3-years post-treatment.
This is an all-comers Registry. Physicians at participating study centers will invite consecutive patients who are prescribed Zephyr Valve treatment to participate in the Registry and allow data collection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing the Zephyr Valve treatment for emphysema/COPD
Device: Zephyr Valve
Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
Also known as: Zephyr System, BLVR
Forced Expiratory Volume in 1 second (FEV1)
The percent of patients achieving an improvement in the post-bronchodilator FEV1 of ≥12% at 12-months.
Time frame: 12 months
Treated Lobar Volume Reduction (TLVR)
Treated Lobar Volume Reduction (TLVR) assessed by High Resolution Computed Tomography (HRCT) at 45-days.
Time frame: 45 days
Absolute Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator
Absolute Change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.
Time frame: Baseline, 6-months, 12-months, 24-months and 36-months
Percent Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator
Percent change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.
Time frame: Baseline, 6-months, 12-months, 24-months and 36-months
Absolute Change in Residual Volume (RV)
Absolute Change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.
Time frame: Baseline, 6-months, 12-months, 24-months and 36-months
Percent Change in Residual Volume (RV)
Percent change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.
Time frame: Baseline, 6-months, 12-months, 24-months and 36-months
Absolute Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Absolute change in St. George's Respiratory Questionnaire (SGRQ) from Baseline to 6-months and 12-months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: Baseline, 6-months and 12-months
Percent Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Percent change in St. George's Respiratory Questionnaire (SGRQ) Total Score from Baseline to 6-months and 12-months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: Baseline, 6-months and 12-months
Absolute Change in Modified Medical Research Council (mMRC)
Absolute Change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.
Time frame: Baseline, 6-months and 12-months
Percent Change in Modified Medical Research Council (mMRC)
Percent change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.
Time frame: Baseline, 6-months and 12-months
Absolute Change in Six-Minute Walk Distance (6MWT)
Absolute change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.
Time frame: Baseline, 6-months and 12-months.
Percent Change in Six-Minute Walk Distance (6MWT)
Percent change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.
Time frame: Baseline, 6-months and 12-months.
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Jun 2022, 17 months.
Of 45 observational studies under Emphysema, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 35. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonx Corporation